As expected, these cells are not affected by estrogens or anti-estrogens, and androgens exert a proliferative effect, whereas AR siRNA or an AR-inhibitor (flutamide, bicalutamide, and enzalutamide) exerts a suppressive effect on these cells, suggesting an AR-dependent mechanism of tumor growth; hence, the possibility of AR-targeting therapy for LAR [87,88]. Here, AR is linked to neoplasm.